Rami Levy - Intercure Chief Canndoc
| INCR Stock | ILS 498.20 28.80 5.46% |
Insider
Rami Levy is Chief Canndoc of Intercure
| Age | 58 |
| Phone | (972) 77 460 5012 |
| Web | www.intercure.co |
Intercure Management Efficiency
The company has return on total asset (ROA) of 0.0538 % which means that it generated a profit of $0.0538 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0736 %, meaning that it generated $0.0736 on every $100 dollars invested by stockholders. Intercure's management efficiency ratios could be used to measure how well Intercure manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Kathleen Veit | Teva Pharmaceutical Industries | N/A | |
| Lena Bernstein | Delek Group | 48 | |
| CPA CPA | Together Startup Network | 52 | |
| Abbas Hussain | Teva Pharmaceutical Industries | 54 | |
| Gilad Meirson | Delek Group | 47 | |
| Kare Schultz | Teva Pharmaceutical Industries | 62 | |
| Stu Schapiro | Delek Group | N/A | |
| Oren Cohen | El Al Israel | N/A | |
| Leehu Hacohen | El Al Israel | N/A | |
| Eli Shani | Teva Pharmaceutical Industries | N/A | |
| Yizhak Eliav | El Al Israel | 48 | |
| Avigal Soreq | El Al Israel | 46 | |
| Andrew Weil | Teva Pharmaceutical Industries | 52 | |
| Advocate Wallace | Delek Group | 46 | |
| Moshe Cohen | El Al Israel | 71 | |
| Amir Weiss | Teva Pharmaceutical Industries | 46 | |
| Deborah Griffin | Teva Pharmaceutical Industries | N/A | |
| Moni Feller | Delek Group | N/A | |
| Janet Vergis | Teva Pharmaceutical Industries | 54 | |
| Yossi Abu | Delek Group | 46 | |
| Yitzhak Oz | Delek Group | 58 | |
Management Performance
| Return On Equity | 0.0736 | |||
| Return On Asset | 0.0538 |
Intercure Leadership Team
Elected by the shareholders, the Intercure's board of directors comprises two types of representatives: Intercure inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Intercure. The board's role is to monitor Intercure's management team and ensure that shareholders' interests are well served. Intercure's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Intercure's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Amos Cohen, Chief Officer | ||
| Alexander Rabinovitch, CEO, Director | ||
| Advocate Ohayon, CoFounder Ltd | ||
| OriMoni Mimon, CoFounder Ltd | ||
| Omri Batzir, Co Controller | ||
| Rami Levy, Chief Canndoc |
Intercure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Intercure a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0736 | |||
| Return On Asset | 0.0538 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 688.06 M | |||
| Shares Outstanding | 45.57 M | |||
| Shares Owned By Insiders | 37.64 % | |||
| Shares Owned By Institutions | 11.60 % | |||
| Price To Earning | 590.59 X | |||
| Price To Book | 1.43 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Intercure Stock
Intercure financial ratios help investors to determine whether Intercure Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Intercure with respect to the benefits of owning Intercure security.